Semaglutide Produces 13.4 kg Weight Loss in Hypothalamic Obesity — A Condition Previously Considered Untreatable
In 26 patients with hypothalamic obesity from brain tumors, semaglutide produced a mean weight loss of 13.4 kg (4.4 BMI points), with 58% losing over 10% and all but one patient losing weight — the first substantial evidence for effective pharmacotherapy in this notoriously treatment-resistant condition.
Quick Facts
What This Study Found
26 patients with hypothalamic obesity treated with semaglutide (median dose 1.6 mg). Mean weight loss: 13.4 kg (95% CI: 10.3-16.5 kg, p<0.001). Mean BMI reduction: 4.4 kg/m² (95% CI: 3.4-5.4, p<0.001). 25/26 patients (96%) lost weight. 15 patients (58%) lost >10% body weight. 2 patients (8%) lost >20%.
Key Numbers
Patients tracked at the Department of Endocrinology, Rigshospitalet. Weight data collected before and after semaglutide initiation.
How They Did This
Real-world retrospective cohort study at Rigshospitalet, Copenhagen (September 2020 to November 2023). 26 patients with acquired hypothalamic obesity (15 females, median age 52, range 18-65). Semaglutide at median dose 1.6 mg (range 0.5-2.5 mg). Weight tracked before and during treatment.
Why This Research Matters
Hypothalamic obesity is one of the most devastating complications of brain tumors and their treatment. Until now, no pharmacotherapy has shown meaningful benefit. This study provides the first real evidence that GLP-1 drugs can work even when the brain's normal appetite circuits are destroyed — suggesting they act through alternative neural pathways.
The Bigger Picture
If semaglutide works when the hypothalamic appetite centers are destroyed, it tells us something fundamental about how GLP-1 drugs cause weight loss — they must be acting through brainstem, hindbrain, or other pathways beyond the hypothalamus. This has implications for understanding GLP-1 drug mechanisms in all patients.
What This Study Doesn't Tell Us
Small cohort (26 patients). Retrospective design without control group. Variable follow-up duration. No information on diet/exercise changes during treatment. The heterogeneous nature of hypothalamic injury (different tumors, different surgical approaches) limits generalizability. Long-term weight stability after treatment not assessed.
Questions This Raises
- ?Which neural pathways does semaglutide use when hypothalamic circuits are destroyed?
- ?Is the weight loss sustainable long-term, or will hypothalamic obesity recur if semaglutide is stopped?
- ?Would higher doses or dual agonists (tirzepatide) produce even better results in this population?
Trust & Context
- Key Stat:
- 96% lost weight All but one of 26 patients with hypothalamic obesity lost weight on semaglutide — remarkable for a condition where diet, exercise, and previous drugs have consistently failed
- Evidence Grade:
- Rated preliminary: small uncontrolled retrospective cohort. However, the consistent response in a notoriously treatment-resistant population makes the signal compelling.
- Study Age:
- Published in 2024. Covers 3+ years of treatment experience (2020-2023) at a major European endocrinology center.
- Original Title:
- Semaglutide treatment of hypothalamic obesity - a real-life data study.
- Published In:
- Pituitary, 27(5), 685-692 (2024)
- Authors:
- Svendstrup, Mathilde, Rasmussen, Aase Krogh, Kistorp, Caroline, Klose, Marianne, Andreassen, Mikkel
- Database ID:
- RPEP-09353
Evidence Hierarchy
Frequently Asked Questions
What is hypothalamic obesity and why is it so hard to treat?
When brain tumors or their treatment damage the hypothalamus — the brain's appetite control center — patients develop severe, relentless weight gain that doesn't respond to diet or exercise. Their BMI in this study jumped from 25 (normal) at diagnosis to 38 (severely obese). Until now, no drug has effectively treated this condition.
How does semaglutide work if the brain's appetite center is damaged?
That's one of the most interesting implications of this study. Since semaglutide worked even when the hypothalamus was damaged, it must be affecting weight through other brain pathways — possibly the brainstem or hindbrain. This changes our understanding of how GLP-1 drugs cause weight loss and suggests they have multiple mechanisms beyond hypothalamic appetite suppression.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09353APA
Svendstrup, Mathilde; Rasmussen, Aase Krogh; Kistorp, Caroline; Klose, Marianne; Andreassen, Mikkel. (2024). Semaglutide treatment of hypothalamic obesity - a real-life data study.. Pituitary, 27(5), 685-692. https://doi.org/10.1007/s11102-024-01429-5
MLA
Svendstrup, Mathilde, et al. "Semaglutide treatment of hypothalamic obesity - a real-life data study.." Pituitary, 2024. https://doi.org/10.1007/s11102-024-01429-5
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide treatment of hypothalamic obesity - a real-life ..." RPEP-09353. Retrieved from https://rethinkpeptides.com/research/svendstrup-2024-semaglutide-treatment-of-hypothalamic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.